People-centered tuberculosis care versus standard directly observed therapy: study protocol for a cluster randomized controlled trial by unknown
TRIALS
Khachadourian et al. Trials  (2015) 16:281 
DOI 10.1186/s13063-015-0802-2STUDY PROTOCOL Open AccessPeople-centered tuberculosis care versus
standard directly observed therapy: study
protocol for a cluster randomized
controlled trial
Vahe Khachadourian1, Nune Truzyan1, Arusyak Harutyunyan1, Michael E. Thompson2, Tsovinar Harutyunyan1
and Varduhi Petrosyan1*Abstract
Background: Tuberculosis is a major public health concern resulting in high rates of morbidity and mortality
worldwide, particularly in low- and middle-income countries. Tuberculosis requires a long and intensive course of
treatment. Thus, various approaches, including patient empowerment, education and counselling sessions, and
involvement of family members and community workers, have been suggested for improving treatment adherence
and outcome. The current randomized controlled trial aims to evaluate the effectiveness over usual care of an
innovative multicomponent people-centered tuberculosis-care strategy in Armenia.
Methods/design: Innovative Approach to Tuberculosis care in Armenia is an open-label, stratified cluster
randomized controlled trial with two parallel arms. Tuberculosis outpatient centers are the clusters assigned to
intervention and control arms. Drug-sensitive tuberculosis patients in the continuation phase of treatment in the
intervention arm and their family members participate in a short educational and counselling session to raise their
knowledge, decrease tuberculosis-related stigma, and enhance treatment adherence. Patients receive the required
medications for one week during the weekly visits to the tuberculosis outpatient centers. Additionally, patients
receive daily Short Message Service (SMS) reminders to take their medications and daily phone calls to assure
adherence and monitoring of treatment potential side effects. Control-arm patients follow the World Health
Organization - recommended directly observed treatment strategy, including daily visits to tuberculosis outpatient
centers for drug-intake. The primary outcome is physician-reported treatment outcome. Patients’ knowledge,
depression, quality of life, within-family tuberculosis-related stigma, family social support, and self-reported
adherence to tuberculosis treatment are secondary outcomes.
Discussion: Improved adherence and tuberculosis treatment outcomes can strengthen tuberculosis control and
thereby forestall tuberculosis and multidrug resistant tuberculosis epidemics. Positive findings on effectiveness of
this innovative tuberculosis treatment people-centered approach will support its adoption in countries with similar
healthcare and economic profiles.
Trial registration: ClinicalTrials.gov registration number: NCT02082340. Date of registration: 4 March 2014.
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Tuberculosis (TB) is an airborne infectious disease
transmitted from person to person, and is a major pub-
lic health concern [1]. In 2012, TB affected more than
8.6 million people worldwide and resulted in 1.3 million
deaths, which made it second only to HIV among lead-
ing causes of infectious disease-related deaths [1]. More
than 80 % of active TB cases in the world are concen-
trated in 22 low- and middle-income countries [2],
where 95 % of all TB deaths occur [3]. Moreover, TB is
the leading cause of death among HIV patients, ac-
counting for 20 % of all causes of deaths among HIV-
infected people [2].
Drug-sensitive strains of TB are treated with four stand-
ard first-line anti-TB drugs. Non-compliance to treatment,
misuse, or mismanagement of medications may lead to
relapse, development of drug-resistant (DR) TB (which re-
quires a more expensive and intensive treatment course),
and even death [4, 5]. According to the 2013 World
Health Organization (WHO) progress report [1], each
year an estimated 450,000 cases and 150,000 deaths occur
globally due to multidrug-resistant TB (MDR-TB). Ac-
cording to 2012 WHO data, 3.6 % of all new TB cases
were MDR-TB, while the rates among previously treated
patients reached 20 % [6]. Among those with MDR-TB,
approximately 9.6 % suffer from extensively drug-resistant
(XDR) strains. In addition to these adverse health conse-
quences, TB places a tremendous economic burden on in-
dividuals and societies [7].
Current treatment approaches and alternative strategies
Currently, WHO recommends directly observed therapy
(DOT) to monitor patients’ adherence to the treatment
regimen, with an optimal dosing frequency of 6 days per
week for new TB patients. In DOT, patients take their
medications while being observed by a healthcare worker,
usually a physician or a nurse [8]. DOT prevents patients
from missing their treatment and thus reduces the devel-
opment of resistance. The outpatient phase of DOT, re-
quiring near daily visits to the health facility, introduces
significant financial and time-related costs to patients [9],
particularly in areas with poor access to health services
[10]. Given such limitations, researchers have implemented
and evaluated various modified or alternative strategies to
improve patients’ adherence to TB treatment [5, 11–14]. A
systematic review of randomized controlled trials did not
suggest enough evidence that DOT compared to self-
administered treatment leads to better treatment outcomes
in people receiving treatment in low-, middle-, and high-
income countries [5].
Empowering patients is recommended as one of key
components of TB treatment [15]. Although several au-
thors have documented the effectiveness of patient em-
powerment in TB treatment [16–19], as identified in areview by Macq et al. in 2007 [20], people-centered so-
lutions have received less attention globally. In low-
resource countries, as an alternative to traditional DOT,
researchers have recruited family members to observe pa-
tients’ medication intake, making treatment easier and less
expensive [10, 21]. Family members are interested in iden-
tifying noncompliance and motivated to encourage and
promote treatment adherence. Several studies [10, 21, 22]
have documented the effectiveness of involving family
members in TB treatment. Some patients value family in-
volvement, especially if the observer is a family decision
maker or is highly respected in the family [23]. Moreover,
WHO has encouraged the development of innovative
people-centered care strategies that, where medically ap-
propriate, enable patient self-management and commu-
nity engagement to improve health outcomes [24, 25].
In recent years, the widespread availability of mobile
phones [26] has spawned numerous health communica-
tions interventions [27–29]. The Short Message Service
(SMS) has been widely used as a reminder for patients
to take their medications and improve treatment adher-
ence [27–29]. Although, SMS reminders have shown sig-
nificant improvement in medication adherence among
patients with HIV [27], asthma [30], and other condi-
tions, a recent review paper evaluating the effectiveness
of SMS reminders for treatment adherence among TB
patient was inconclusive, identifying methodological lim-
itations of prior studies and suggesting further con-
trolled trials evaluating the role of SMS reminders for
TB adherence [31].
Patient counseling and education have been found to
improve treatment adherence among TB patients [11, 32],
which in turn, results in better treatment outcomes and
improvement in the patients’ quality of life [33].
Treatment adherence has been associated with many
different factors [9], including social support, healthcare
satisfaction, and disease-related knowledge. Multicompo-
nent interventions were found to improve treatment adher-
ence [34]. Hence, our team developed a multicomponent
innovative approach to TB care to enable self-administered
drug intake by empowered TB patients - supervised by a
trained family member and supported by patient and family
counseling and reminders - to improve treatment adher-
ence and outcome, and thereby forestall TB and multidrug
resistant TB epidemics. The innovative treatment approach
integrates several educational, technological, and social
evidence-based components.
Aims and objectives
The current randomized controlled trial aims to evaluate
the effectiveness of an alternative multicomponent TB
outpatient care strategy consisting of the following: 1)
education and counseling for drug-sensitive TB patients
and their family members, 2) self-administered drug-
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SMS reminders to TB patients, and 4) daily phone calls
to supporting family members. The research team is
measuring if this alternative TB care strategy offers
advantages over the regular DOT in terms of treatment
outcomes, patients’ and family members’ knowledge about
TB, patients’ depression status and quality of life, TB-
related stigma, family social support, and self-reported ad-
herence to TB treatment.
Methods/design
Trial design
This is an open-label, stratified cluster randomized con-
trolled superiority trial with two parallel equal arms
(intervention and control) conducted in Armenia. TB
outpatient centers defined the clusters, with equal num-
bers of clusters assigned to intervention and control
arms. We performed a cluster-level random assignment
of drug sensitive TB patients to intervention and control
arms to mitigate potential contamination of participants
in the control arm.
Study setting and eligibility criteria for clusters
The intervention takes place during the continuation
phase of TB treatment and is implemented through
Armenia’s TB outpatient centers. TB centers having a
minimum patient load of five drug-sensitive TB patients
in 2012 were included to ensure that centers with very
small patient loads did not decrease the study’s power.
Out of 60 TB outpatient centers in Armenia, 52 met the
inclusion criterion.
Eligibility criteria for individual tuberculosis patients
Study participants are patients starting their continu-
ation phase of TB treatment in selected outpatient TB
care centers. The patient eligibility criteria are as follows:
1. Having a diagnosis of drug sensitive pulmonary TB,
2. Starting the continuation phase of TB treatment
between March and-December 2014,
3. Being at least 18 years old at the time of enrolment,
and
4. The ability to communicate in Armenian.
The eligibility status of each patient is subject to verifi-
cation by the corresponding TB outpatient center phys-
ician and the psychologist of the National Tuberculosis
Control Center (NTC).
Assignment of intervention/randomization
We stratified the TB outpatient centers (clusters) based
on their drug-sensitive patient load in 2012 and their treat-
ment outcomes (performance). We classified TB out-
patient centers as small, average, or large, and performanceoutcomes as below average, average, or above average,
yielding nine distinctive cluster categories. We applied
computer-assisted block randomization to assure rela-
tively equal number of cluster representatives from each
of these nine categories in the intervention and control
arms. The process yielded 26 centers in each arm.
Cluster level interventions
TB physicians in both intervention and control clusters
are instructed and requested to inform the study team
whenever they have a patient who meets the inclusion
criteria. In addition, all TB physicians and nurses in the
intervention clusters are trained on the study protocols
and procedures. They are instructed to closely follow the
study protocols and perform study-related paper work,
including the distribution and collection of weekly side
effect and medication intake forms (applicable only to
intervention clusters). Physicians in the intervention
clusters also are trained to provide patients with a one-
week supply (6 days of pills) of TB medications using
the designated pillboxes.
Individual level interventions
Patients in the intervention arm are asked to identify a
family member to provide support during the course of
treatment. The patients, their supportive family member,
and other interested family members, as permitted by
the patient, participate in TB educational and psycho-
logical counseling session provided by a team of a psych-
ologist and a nurse (interventionists).
The interventionists participated in a training-of-
trainers course before starting fieldwork. The interactive
TB educational and psychological counseling session
covers various topics, including TB symptoms, TB route
of transmission, TB treatment strategies, importance of
treatment adherence, prevention and infection control,
handling side effects, addressing TB-related stigma and
common myths. Average duration of each session is ap-
proximately 90 minutes. The primary objective is to em-
power TB patients and their family members to take
responsibility for the treatment.
After the educational and counseling session, patients
visit their physicians weekly in the TB outpatient centers
for a medical check-up and to receive the prescribed TB
medication for that week. The supportive family mem-
bers are responsible for following the TB patients and
supporting their adherence to the treatment regimen.
The supportive family members also are responsible for
completing a form each week documenting medication
intake and observed side effects. Patients return the
completed form to the TB physician during the next
week’s visit.
Patients receive daily SMS messages each morning
reminding them to take their medications on time, and
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physician for their weekly supply. The supportive family
members receive daily phone calls from the research
team each evening to inquire about side effects related
to TB medication and to inquire if the patients are tak-
ing their TB medications on a timely basis. During these
calls, patients and family members also are offered add-
itional psychological advice and support if needed.
Patients in the intervention arm who lack a supporting
family member also assume all the responsibilities de-
fined for the supportive family member.
Patients in the control arm follow the regular DOT
strategy for continuation phase, in line with the guide-
lines of Armenia’s Ministry of Health and WHO recom-
mendations: it includes taking prescribed TB medication
6 days per week while being observed by a health-care
provider. The patients in this group do not receive any
additional intervention.
Outcomes and additional measurements
The primary outcome of this controlled trial is TB treat-
ment outcome according to WHO definitions as re-
corded in the medical file and reported to the NTC.
Treatment outcomes are classified as follows: cured,
completed treatment, dead, failed, defaulted, and trans-
ferred [35]. A patient is considered to be successfully
treated if he/she has a cured or completed treatment
outcome. All other categories are considered as an un-
successful treatment outcome.
Secondary outcome measures include patients’ know-
ledge, depression status, quality of life, within-family TB-
related stigma, family social support, and self-reported
adherence to TB treatment. In addition, we measure fam-
ily members’ knowledge, depression status, social supportTable 1 Outcome variables
Variable Source
Treatment outcomes National Tuberculosis Control Center rep
Possible Depression Patient survey
Quality of life Patient survey
TB knowledge Patient survey
TB-related stigma within family Patient survey
Social support Patient survey
Treatment adherence Patient survey
Possible depression Family member survey
TB knowledge Family member survey
TB-related stigma Family member survey
Social support Family member survey
aAt the beginning of continuation phase of treatment/before intervention
bAfter completion of continuation phase of TB treatment
TB, tuberculosistoward TB patient, and TB-related stigma. All the second-
ary outcomes other than self-reported treatment adher-
ence are measured at T0 (baseline) and T1 (follow-up).
Self-reported treatment adherence is assessed only at
T1. The knowledge variable is constructed from correct
responses to five items adapted from previous work
[36–38]. Depression is assessed using a modified ver-
sion of the Center for Epidemiological Studies Depres-
sion (CES-D) scale [39]; the Armenian translation is
validated and the negatively formulated 16 items show
high diagnostic accuracy and good factorial structure
[40, 41]. We have used a modified version of a validated
scale to measure within-family TB related stigma [42]
and the Berlin social support scale [43] to measure so-
cial support of family members toward TB patients. We
have applied EQ-5D to obtain data on quality of life of
patients [44].
Measurements on sociodemographic characteristics
including age, gender, socioeconomic status, education,
marital status, and health behavior (smoking and drink-
ing) are obtained to verify the validity of randomization
and, if necessary, to control for the potentially con-
founding effects of these variables on the primary and
secondary outcomes. Table 1 summarizes the study out-
comes and presents the frequency of data collection.
Baseline and follow-up surveys are interviewer-admin-
istered. Given the characteristics of the intervention
protocol, blinding interviewers assessing secondary out-
comes (knowledge about TB, depression, quality of life,
within-family TB-related stigma, and family social sup-
port) at baseline is not possible. However, interviewers
are blinded for the assessment of secondary outcomes at
follow-up. The treatment outcome (primary outcome
variable of interest) is assessed and reported by theTimeline
Type T0a T1b
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regular reporting to the NTC; this process is completely
independent of the research team.
Recruitment
The NTC informed physicians and nurses in all 52 eligible
TB outpatient centers (clusters) of the study and invited
them to be involved in the trial. All agreed to participate.
Health-care workers in the intervention and control clus-
ters are instructed and requested to report on all new and
previously treated drug sensitive TB patients who start
their continuation phase of TB treatment in the selected
TB outpatient centers. The NTC psychologist, who had
special training on the protocols and procedures of this
study, makes the initial contact with the eligible patients
following these steps: 1) the TB physicians report eligible
patients to NTC, 2) the NTC psychologist contacts eli-
gible patients over the phone, 3) the NTC psychologist
verifies patients’ eligibility, 4) the NTC psychologist pre-
sents the study information briefly in a phone call and gets
the patients’ consent to share their contact information
with the research team, and 5) the NTC psychologist
schedules a face-to-face meeting between the TB patient
and the research team members.
The NTC psychologist also asks patients about house-
hold size and the number of family members aware of the
TB diagnosis. If it becomes evident that all members of
the patient’s family know about his/her disease and if the
patient expresses desire for family members to receive TB
counseling, then the NTC psychologist arranges an appro-
priate place (usually home of the patient), date and time
for the counseling session. We ask the patients to identify
potential supporters from their family members who par-
ticipate in the counseling session to support them during
their treatment period. If the patient lives alone or is un-
willing for any family member to support him/her during
the treatment and to participate in the counseling session,
we set a convenient place (usually TB outpatient center),
date and time for the TB patient’s counseling session.
Patients are enrolled within 15 days from the start of
their continuation phase of treatment. The average duration
of the continuation phase for the drug sensitive TB treat-
ment is about four months. We anticipate completion of
recruitment and data collection within 12 months from the
start of the field work.
Sample size
We based sample size calculations for this study on the
treatment outcome as the main variable of interest. In
2012, 1,200 drug sensitive TB patients received the con-
tinuation phase of their treatment in TB outpatient cen-
ters. Utilizing the 2012 data on the number of patients
and outcomes at each TB outpatient center, we identified
52 eligible clusters from the 60 centers. We calculatedthe intracluster correlation to be 0.04 and estimated the
design effect as 1.6 [45]. The initial sample size calcula-
tion used a 10 % difference in the primary outcome [38],
an alpha of 0.05 and power of 80 % and yielded a sample
size of 95. Considering the potential for losses to follow-
up taking a more conservative approach, we used a
design effect of two; thus, the required sample size was
calculated to be 190 in each arm.Data collection
We utilize interviewer-administered face-to-face surveys
to collect data on secondary outcomes. All patients and
their family supporters (if any) in the intervention and
control arms are asked to complete an interviewer-
administered questionnaire at baseline (T0) and after
completion of their TB treatment (T1, follow-up).Data management
All the completed survey questionnaires are reviewed by
a research team member for missing data and unusual
responses. Data are double entered into an SPSS (version
21.0) database; after completing entry, the two databases
will be reconciled to minimize data entry related errors.
The research team directly enters the data collected
during daily calls made to the supporting family mem-
bers of patients in the intervention arm into an Epi-info
database.
The complete de-identified dataset of the trial will be
publicly available when finalized.Statistical analyses
Statistical analyses will follow the intention-to-treat
principle [46]. We will assess randomization across the
two arms by comparing sociodemographic characteris-
tics and other potential confounding variables using chi-
square for binary and categorical variables, t-test, or
other equivalent nonparametric tests, as appropriate, for
continuous variables.
The primary outcome (treatment outcome) will be an-
alyzed using generalized mixed effect model applying bi-
nomial distribution, logistic regression [47]. The status
of randomization (intervention/control) will be included
as an independent variable; to account for the clustered
design we will treat clusters as a random effect. Potential
confounding variables (age, gender, socioeconomic sta-
tus, and others) with significant differences across inter-
vention and control arms will be included as fixed
factors. Secondary outcomes including knowledge, de-
pression status, quality of life, within family TB-related
stigma, and family social support also will be tested
using generalized linear mixed effect models using logis-
tic regression or linear regression, as appropriate. The
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assessment as a covariate.
We will report all the descriptive and inferential statis-
tics results with their 95 % confidence intervals.
Patient safety and monitoring of adverse events
TB patients included in this trial are drug-sensitive and
have completed their intensive treatment phase. We take
special efforts to minimize potential adverse events. All
patients in the intervention arm undergo routine med-
ical check-ups during weekly visits to TB outpatient cen-
ters. Moreover, the side effect report form is completed
daily and reported by telephone to the research team,
allowing the research team to quickly report concerns to
the corresponding TB physician for follow-up. Side ef-
fects among those patients in the control arm are taken
care during their regular daily visits to TB outpatient
centers.
Research ethics
The American University of Armenia Institutional Review
Board (IRB) reviewed and approved the study protocol
(# AUA-2014-020). Study-related activities started only
after receiving IRB approval.
In this multicomponent intervention, we randomized
at the TB outpatient center (cluster) level. Individual pa-
tient assignments therefore are determined by their geo-
graphically assigned TB outpatient center. Patients (and
their family members) can only participate in the inter-
vention arm after reading and signing a written consent
form. Patients opting out of their assignment and those
in the control arm receive traditional DOT for the con-
tinuous phase of TB treatment.
Data safety
All patients are assigned a unique ID. The question-
naires and other data collection forms contain no identi-
fiable information. Hardcopy questionnaires are stored
in a locked safe in the research center at the American
University of Armenia School of Public Health and will
be archived for at least three years. Electronic databases
are password protected and select members of the re-
search team have access to the databases. No identifiable
information is provided to persons outside the research
team.
Discussion
TB poses a major burden on populations, particularly
among those living in low- and middle- income coun-
tries. Any improvement in TB treatment strategies can
have a significant public health and economic import-
ance. Improved control and management of TB can lead
to better treatment outcomes, thereby decreasing health
inequalities, morbidity, mortality, and economic costsassociated with the disease. Rigorously evaluated alterna-
tive people-centered strategies, if successful, can be im-
plemented in countries with similar healthcare and
economic profiles and help to forestall TB and multidrug-
resistant TB epidemics.
Trial status
At the time of submission of this manuscript, the trial is
ongoing; it began enrolment in March 2014.
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